Therapeutic Effect and Evaluation of Recombinant Human Interleukin-11 on Chemotherapy-induced Thrombocytopenia in Patients with Acute Myeloid Leukemia

Objective To observe and evaluate the efficacy and adverse reactions of recombinant human interleukin-11(rhIL-11) on chemotherapy-induced thrombocytopenia in patients with acute myeloid leukemia.Methods 45 acute myeloid leukemia patients with chemotherapy-induced thrombocytopenia were randomly divided into experimental group and control group.Cases in the experimental group received subcutaneous injection of rhIL-11[30μg/(kg d)] until the platelet count recovered to ≥50×109/L,while those in the control group were not administered with rhIL-11.Results The mean platelet counts in the experimental group and control group before chemotherapy had no significant difference(P0.05).The platelet count after chemotherapy in the experimental group was significantly higher than that in the control group(P0.05).The time of platelet count increasing to 50×109/L in the experimental group was significantly shorter than that in the control group(P0.05).The mean times and volume of platelet infusion in the experimental group after chemotherapy was decreased than that in the control group(P0.05).The symptoms induced by the rhIL-11 was tolerable and disappeared when subcutaneous injection of rhIL-11 was stopped.Conclusion Administration of rhIL-11 in chemotherapy-induced thrombocytopenia patients with acute myeloid leukemia can not only enhance the platelet counts and shorten the recovery time of thrombocytopenia,but also has only mild adverse reactions.